多发性骨髓瘤双特异性抗体治疗感染管理中国专家共识(2026)
双特异性抗体(BsAb)治疗复发/难治性多发性骨髓瘤(MM)可显著延长生存期,但独特免疫机制导致感染风险明显增加,总体感染发生率为45.8%~80%。中华医学会血液学分会浆细胞疾病学组与中国医师协会多发性骨髓瘤专业委员会基于最新证据制定本共识,规范MM患者接受BsAb治疗过程中的感染监测、预防与处理。
要点
- BsAb治疗MM总体感染发生率为45.8%~80%,是影响治疗安全性的关键问题。
- BsAb通过持续T细胞激活、B细胞耗竭及低丙种球蛋白血症增加感染风险。
- 共识适用于MM患者BsAb治疗中的感染监测、预防与处理。
核心结论
- BsAb治疗MM总体感染发生率为45.8%~80%,需规范感染监测、预防与处理以保障治疗安全。
研究设计与样本
- 中华医学会血液学分会浆细胞疾病学组与中国医师协会多发性骨髓瘤专业委员会基于最新证据制定本共识。
主要发现
- BsAb通过连接T细胞与肿瘤细胞表面抗原诱导肿瘤杀伤,显著延长患者生存期。
- BsAb独特免疫激活机制导致持续T细胞激活、B细胞耗竭及低丙种球蛋白血症,使感染风险明显增加。
- MM患者接受BsAb治疗的总体感染发生率为45.8%~80%。
关键数值与推荐
- 共识主要适用于MM患者接受BsAb治疗过程中的感染监测、预防与处理。
临床怎么用
- 提升对BsAb治疗相关感染并发症的识别与管理能力,使患者获得最佳无进展生存期和总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bispecific antibody (BsAb) is a novel immunotherapy for relapsed/refractory multiple myeloma (MM), which induces tumor cell killing by bridging T cells with tumor surface antigens and has significantly prolonged patient survival. However, the unique immune activation mechanism of BsAb leads to sustained T-cell activation, B-cell depletion, and hypogammaglobulinemia, markedly increasing infection risk in patients. The overall incidence of infection is 45.8% -80%, becoming a critical issue affecting treatment safety. With the widespread application of BsAb in China, understanding of related infections has been continuously deepened, and infection monitoring techniques, prevention protocols, and treatment strategies are also being optimized. To standardize the prevention and control of BsAb-related infections in MM patients in China, the Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and Chinese Myeloma Committee-Chinese Hematology Association have developed this consensus based on the latest evidence. This consensus mainly applies to the infection monitoring, prevention, and management during the treatment of BsAb in MM patients, aiming to enhance the recognition and management capability of infection-related complications and enable patients to achieve optimal progression-free survival and overall survival. 双特异性抗体(BsAb)是治疗复发/难治性多发性骨髓瘤(MM)的新型免疫疗法,通过连接T细胞与肿瘤细胞表面抗原诱导肿瘤杀伤,显著延长了患者的生存期。然而,BsAb独特的免疫激活机制导致持续T细胞激活、B细胞耗竭及低丙种球蛋白血症,使患者感染风险明显增加,总体感染发生率为45.8%~80%,已成为影响治疗安全性的关键问题。随着BsAb在我国的广泛应用,对其相关感染的认识不断加深,感染监测技术、预防方案及治疗策略亦在持续优化。为规范我国MM患者接受BsAb治疗相关感染的防控实践,中华医学会血液学分会浆细胞疾病学组与中国医师协会多发性骨髓瘤专业委员会基于最新证据制定了本版共识。本共识主要适用于MM患者接受BsAb治疗过程中的感染监测、预防与处理,提升对感染相关并发症的识别与管理能力,使患者获得最佳的无进展生存期和总生存期。.
引用
- [Chinese expert consensus on infection management in multiple myeloma patients treated with bispecific antibody (2026)]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706152. doi:10.3760/cma.j.cn121090-20260211-00088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。